摘要
目的探讨血管内皮生长因子(VEGF)、表皮生长因子受体(EGFR)及人表皮生长因子受体-2(HER-2)在结直肠癌中的表达及其与临床病理特征的关系和意义。方法采用免疫组织化学法检测结直肠癌、绒毛状腺瘤、管状腺瘤及正常组织中VEGF、EGFR和HER-2的表达,分析各组间表达的差异及其与临床病理参数的关系。结果在结直肠癌、绒毛状腺瘤、管状腺瘤和正常结直肠组织中VEGF的阳性率分别为74%(51/69)、61%(17/28)、27%(4/15)、0(0/15),各组间表达的差异有统计学意义(χ2=33.663,P=0.000);EGFR的阳性率分别为43%(30/69)、21%(6/28)、20%(3/15)、0(0/15),各组间表达的差异有统计学意义(χ2=13.877,P=0.003);HER-2的阳性率分别为17%(12/69)、0(0/28)、0(0/15)、0(0/15),各组间表达的差异有统计学意义(χ2=11.140,P=0.011)。②在结直肠癌,VEGF阳性率与淋巴结转移(χ2=7.442,P=0.006)、分化程度(χ2=5.519,P=0.023)有关,与患者性别(χ2=0.099,P=0.754)、年龄(χ2=1.998,P=0.158)、部位(χ2=0.209,P=0.648)无关;EGFR阳性率与淋巴结转移(χ2=5.113,P=0.024)、分化程度(χ2=4.495,P=0.034)有关,与患者性别(χ2=0.090,P=0.765)、年龄(χ2=0.193,P=0.660)、部位(χ2=1.002,P=0.317)无关;HER-2的表达与患者的性别(χ2=0.451,P=0.502)、年龄(χ2=0.793,P=0.373)、部位(χ2=0.019,P=0.889)、分化程度(χ2=0.721,P=0.396)、淋巴结转移(χ2=0.613,P=0.434)均无关。③VEGF、EGFR和HER-2表达在结直肠癌中表达两两呈正相关(r=0.388,P=0.001;r=0.273,P=0.023;r=0.292,P=0.015)。结论 VEGF、EGFR和HER-2的表达与结直肠癌的发生发展密切相关,VEGF、EGFR和HER-2表达在结直肠癌中表达两两呈正相关,联合检测三者的表达能更准确地评估结直肠癌的生物学特征及预后。
Objective To investigate the expression and significance of vascular endothelial growth factor （VEGF）, epidermal growth factor receptor （EGFR） and human epidermal receptor-2 （HER-2） in colorectal carcinoma. Methods Immunohistochemistry was employed to detect the expression of VEGF, EGFR and HER-2 in colorectal carcinoma, villous adenoma, tubular adenoma and normal colorectal tissues. This entailed analysis on the difference and clinieopathologic parameters among all groups. Results The positivity of VEGF expression was 74% （51/69）, 61% （17/28）, 27% （4/15） and 0 （0/15） in colorectal carcinoma, villous adenoma, tubular adenoma and normal colorec- tal tissue （X2=33.663, P=0.000）, respectively. These figures were 43% （30/69）, 21% （6/28）, 20% （3/15） and 0 （0/15） for the positivity of EGFR （X2=13.77,P=-0.003）, as well as 17% （12/69）, 0 （0/28）, 0 （0/15） and 0 （0/15） for the positivity of HER-2 （A,Z=1 1.140, P=0.011）, respectively. In patients with colorectal carcinoma, VEGF expression was related to lymphatic metastasis （X2=7.442, P=0.006） and tumor differentiation （X2=5.519, P=0.023）, but not sex （x^2=0.099, P= 0.754）, age （x^2=1.998, P=0.158） or tumor sites （x^2=0.209, P=0.648）. EGFR expression was associated with lymphatic metastasis （X2=5.113, P=0.024） and differentiation degree （X2=0.495, P=-0.034）, but not sex （X2=0.090, P=-0.765）, age （ x^2=0.193, P=-0.660） or tumor＇s location （A~=l.O02,/9=-0.317）. The expression of HER-2 was not correlated with sex （X2= 0.451, P=-0.502）, age （Xz=0.793, P=0.373）, tumor＇s location （Xz=0.019, P=0.889）, differentiation （X2=0.721,P=-0.396） or lymphatic metastasis （x^2=0.613, P=0.434）. There was a positive correlation between expression of VEGF and EGFR,between VEGF and HER-2 as well as between EGFR and HER-2 in colorectal carcinoma （r=-0.388, P=0.001; r=-0.273, P=0.023; r=0.292, P=0.015）. Conclusion VEGF, EGFR and HER-2 are closely correlated wit
出处
《中国药物与临床》
CAS
2013年第10期1263-1266,共4页
Chinese Remedies & Clinics
基金
山西省科技攻关项目(20110313021)
